Page last updated: 2024-11-03

proglumide and Acute Edematous Pancreatitis

proglumide has been researched along with Acute Edematous Pancreatitis in 34 studies

Proglumide: A drug that exerts an inhibitory effect on gastric secretion and reduces gastrointestinal motility. It is used clinically in the drug therapy of gastrointestinal ulcers.
proglumide : A racemate composed of equal amounts of (R)- and (S)-proglumide. A non-selective CCK antagonist that was used primarily for treatment of stomach ulcers, but has been replaced by newer drugs.
N(2)-benzoyl-N,N-dipropyl-alpha-glutamine : A dicarboxylic acid monoamide obtained by formal condensation of the alpha-carboxy group of N-benzoylglutamic acid with dippropylamine.

Research Excerpts

ExcerptRelevanceReference
"These results indicate that oral administration of loxiglumide may be useful in the treatment of patients with acute, painful attacks of chronic pancreatitis, and 600 mg/d is recommended as a beneficial dosage."9.10Clinical evaluation of oral administration of a cholecystokinin-A receptor antagonist (loxiglumide) to patients with acute, painful attacks of chronic pancreatitis: a multicenter dose-response study in Japan. ( Matsuno, S; Satake, K; Shiratori, K; Takeuchi, T, 2002)
"The therapeutic effects of loxiglumide on human acute pancreatitis was investigated in 104 Japanese institutes from October 1992 to March 1994."9.09Clinical evaluation of cholecystokinin-A- receptor antagonist (loxiglumide) for the treatment of acute pancreatitis. A preliminary clinical trial. Study Group of Loxiglumide in Japan. ( Harada, H; Ochi, K; Satake, K, 1999)
" In this report, the effects of loxiglumide and gabexate mesilate were studied on three experimental acute pancreatitis models induced by caerulein, sodium taurocholate + caerulein and closed duodenal loop."7.70Effects of loxiglumide on experimental acute pancreatitis in comparison with gabexate mesilate. ( Fujii, M; Kasai, H; Kimura, K; Saito, T; Tominaga, K, 1998)
"Trypsinogen activation peptide (TAP) concentration and alpha 2-macroglobulin-trypsin complex (alpha 2M-T) activity were measured in two experimental models of acute pancreatitis in rats to evaluate the significance of activation of trypsinogen in acute pancreatitis."7.69Activation of trypsinogen in experimental models of acute pancreatitis in rats. ( Hayakawa, T; Hirao, S; Kitagawa, M; Nakae, Y; Naruse, S; Yamamoto, R, 1995)
"The effect of long term administration of a synthetic cholecystokinin (CCK) receptor antagonist CR1505 (loxiglumide) on pancreatitis was examined in rats after pancreatic duct ligation (PL) with an internal bile fistula."7.69Lack of effect of cholecystokinin receptor antagonist (CR1505) on recovery of experimental pancreatitis after pancreatic duct occlusion in rats. ( Funakoshi, A; Jimi, A; Mishima, Y; Miyasaka, K; Tomita, H, 1994)
"The aim of this study was to investigate the effect of endogenous cholecystokinin (CCK) on pancreatic regeneration after acute hemorrhagic pancreatitis."7.69Role of endogenous cholecystokinin in the regeneration of pancreatic tissue after acute hemorrhagic pancreatitis in rats. ( Kimura, T; Nakano, I; Nawata, H; Song, W; Yamaguchi, H, 1996)
"We evaluated the effects of a new cholecystokinin (CCK) receptor antagonist, loxiglumide, in a model of mild pancreatitis induced by repeated injections of cerulein and in a severe necrotizing form of pancreatitis induced by retrograde ductal injection of sodium taurocholate (NaTc) in rats."7.68Effect of a new cholecystokinin receptor antagonist loxiglumide on acute pancreatitis in two experimental animal models. ( Fujii, M; Itoh, H; Nakamura, T; Okabayashi, Y; Otsuki, M; Tani, S, 1990)
"The present study investigates the effect of CCK-receptor blockade on taurocholate-induced pancreatitis in rats using the potent antagonist loxiglumide."7.68Influence of the CCK-antagonist loxiglumide on bile-induced experimental pancreatitis. ( Creutzfeldt, W; Fussek, M; Leonhardt, U; Seidensticker, F; Stöckmann, F, 1991)
"Involvement of endogenous cholecystokinin (CCK) in the development of acute pancreatitis induced in rats by closed duodenal loop (CDL) was examined, and the effects of the potent and specific CCK receptor antagonist loxiglumide on this model of acute pancreatitis were evaluated."7.68Involvement of endogenous cholecystokinin in the development of acute pancreatitis induced by closed duodenal loop. ( Itoh, H; Koide, M; Okabayashi, Y; Otsuki, M; Tani, S, 1993)
"The therapeutic effect and the mechanism of action of the synthetic trypsin inhibitor camostate were studied in a rat model of acute interstitial pancreatitis induced by four subcutaneous injections of 20 micrograms/kg body weight of cerulein at hourly intervals."7.68Beneficial effects of the synthetic trypsin inhibitor camostate in cerulein-induced acute pancreatitis in rats. ( Fuji, M; Fujisawa, T; Itoh, H; Nakamura, T; Okabayashi, Y; Otsuki, M; Tani, S, 1990)
"The aim of this study was to elucidate whether cholecystokinin (CCK) had a role in the occurrence and/or in the development of experimental acute pancreatitis in rats, and furthermore to find the possibility for the treatment of acute pancreatitis with a CCK antagonist, proglumide."7.67Possible role of cholecystokinin in the development of acute pancreatitis in rats. ( Fujimura, M; Shinya, H, 1989)
"The effects of cholecystokinin receptor antagonist CR 1392 was studied in a model of mild acute pancreatitis induced in rats by four subcutaneous injections of the secretagogue caerulein."7.67Effect of a new cholecystokinin receptor antagonist CR 1392 on caerulein-induced acute pancreatitis in rats. ( Baba, S; Fujii, M; Fujisawa, T; Itoh, H; Nakamura, T; Okabayshi, Y; Otsuki, M; Tani, S, 1989)
"Rats with acute experimental pancreatitis were treated with the cholecystokinin (CCK)-receptor antagonist proglumide."7.67Proglumide treatment in bile-induced acute experimental pancreatitis. ( Ihse, I; Larsson, L; Lilja, I; Tarpila, E, 1988)
"The effects of the cholecystokinin (CCK)-receptor antagonist proglumide, the protease inhibitor gabexate, and the hormones secretin and cholecystokinin-octapeptide (CCK-8) were studied in a model of acute hemorrhagic pancreatitis induced by feeding mice a choline-deficient, ethionine-supplemented (CDE) diet."7.67Beneficial effects of cholecystokinin-receptor blockade and inhibition of proteolytic enzyme activity in experimental acute hemorrhagic pancreatitis in mice. Evidence for cholecystokinin as a major factor in the development of acute pancreatitis. ( Ferrell, LD; Grendell, JH; Liddle, RA; Niederau, C, 1986)
"Loxiglumide treatment, although significantly decreasing protein output, had no influence on pancreatic weight, protein and DNA contents, or pancreatic juice flow but increased the amylase and lipase contents compared to those of the saline-treated postpancreatitic rats."5.29Effect of the cholecystokinin receptor antagonist loxiglumide on pancreatic exocrine function in rats after acute pancreatitis. ( Nakano, S; Otsuki, M; Tachibana, I, 1995)
"Loxiglumide has a simple, non-polypeptidic chemical structure and may be a candidate for clinical investigations in man, e."5.27Loxiglumide protects against experimental pancreatitis. ( Bani, M; Cereda, R; Chisté, R; Makovec, F; Pacini, MA; Revel, L; Setnikar, I, 1987)
"These results indicate that oral administration of loxiglumide may be useful in the treatment of patients with acute, painful attacks of chronic pancreatitis, and 600 mg/d is recommended as a beneficial dosage."5.10Clinical evaluation of oral administration of a cholecystokinin-A receptor antagonist (loxiglumide) to patients with acute, painful attacks of chronic pancreatitis: a multicenter dose-response study in Japan. ( Matsuno, S; Satake, K; Shiratori, K; Takeuchi, T, 2002)
"The therapeutic effects of loxiglumide on human acute pancreatitis was investigated in 104 Japanese institutes from October 1992 to March 1994."5.09Clinical evaluation of cholecystokinin-A- receptor antagonist (loxiglumide) for the treatment of acute pancreatitis. A preliminary clinical trial. Study Group of Loxiglumide in Japan. ( Harada, H; Ochi, K; Satake, K, 1999)
" In this report, the effects of loxiglumide and gabexate mesilate were studied on three experimental acute pancreatitis models induced by caerulein, sodium taurocholate + caerulein and closed duodenal loop."3.70Effects of loxiglumide on experimental acute pancreatitis in comparison with gabexate mesilate. ( Fujii, M; Kasai, H; Kimura, K; Saito, T; Tominaga, K, 1998)
"Trypsinogen activation peptide (TAP) concentration and alpha 2-macroglobulin-trypsin complex (alpha 2M-T) activity were measured in two experimental models of acute pancreatitis in rats to evaluate the significance of activation of trypsinogen in acute pancreatitis."3.69Activation of trypsinogen in experimental models of acute pancreatitis in rats. ( Hayakawa, T; Hirao, S; Kitagawa, M; Nakae, Y; Naruse, S; Yamamoto, R, 1995)
"The effect of long term administration of a synthetic cholecystokinin (CCK) receptor antagonist CR1505 (loxiglumide) on pancreatitis was examined in rats after pancreatic duct ligation (PL) with an internal bile fistula."3.69Lack of effect of cholecystokinin receptor antagonist (CR1505) on recovery of experimental pancreatitis after pancreatic duct occlusion in rats. ( Funakoshi, A; Jimi, A; Mishima, Y; Miyasaka, K; Tomita, H, 1994)
"Effects of a new cholecystokinin (CCK)A-receptor antagonist, T-0632 [sodium (S)-1-(2-fluorophenyl)-2, 3-dihydro-3-[(3-isoquinolinylcarbonyl) amino]-6-methoxy-2-oxo-1H-indole-3-propanoate], on caerulein-induced and pancreatic duct ligation-induced pancreatitis models were studied and compared with the CCKA-receptor antagonist loxiglumide and the orally active protease inhibitor camostate, respectively."3.69Effect of T-0632, a cholecystokininA receptor antagonist, on experimental acute pancreatitis. ( Endo, T; Kume, E; Nagasaki, M; Shikano, T; Taniguchi, H; Yomota, E, 1997)
"The aim of this study was to investigate the effect of endogenous cholecystokinin (CCK) on pancreatic regeneration after acute hemorrhagic pancreatitis."3.69Role of endogenous cholecystokinin in the regeneration of pancreatic tissue after acute hemorrhagic pancreatitis in rats. ( Kimura, T; Nakano, I; Nawata, H; Song, W; Yamaguchi, H, 1996)
" Two kinds of pancreatic secretagogues, one category of which induces acute pancreatitis (cholecystokinin and carbachol) and another which does not induce acute pancreatitis (bombesin, CCK-JMV-180, and secretin), as well as lecithin were used to investigate the effect of changes in membrane fluidity of acini."3.69Effects of cholecystokinin and carbachol on membrane fluidity in pancreatic acini. ( Arii, S; Funaki, N; Imamura, M; Imamura, T; Kohmoto, M; Ohshio, G; Okada, N; Sasaoki, T; Tanaka, J; Tanaka, T; Wang, ZH; Yoshida, M, 1996)
"Involvement of endogenous cholecystokinin (CCK) in the development of acute pancreatitis induced in rats by closed duodenal loop (CDL) was examined, and the effects of the potent and specific CCK receptor antagonist loxiglumide on this model of acute pancreatitis were evaluated."3.68Involvement of endogenous cholecystokinin in the development of acute pancreatitis induced by closed duodenal loop. ( Itoh, H; Koide, M; Okabayashi, Y; Otsuki, M; Tani, S, 1993)
"The therapeutic effect and the mechanism of action of the synthetic trypsin inhibitor camostate were studied in a rat model of acute interstitial pancreatitis induced by four subcutaneous injections of 20 micrograms/kg body weight of cerulein at hourly intervals."3.68Beneficial effects of the synthetic trypsin inhibitor camostate in cerulein-induced acute pancreatitis in rats. ( Fuji, M; Fujisawa, T; Itoh, H; Nakamura, T; Okabayashi, Y; Otsuki, M; Tani, S, 1990)
"Availability of specific cholecystokinin (CCK) receptor antagonists has the potential for contributing to delineation of the role of CCK in the development of pancreatitis and, perhaps, development of new therapeutic agents for treatment of the disorder."3.68The effect of the CCK receptor antagonist CR 1409 on bile reflux pancreatitis in the opossum. ( Andrus, CC; Kaminski, DL; Larsen, F; Schlarman, D, 1991)
"The present study investigates the effect of CCK-receptor blockade on taurocholate-induced pancreatitis in rats using the potent antagonist loxiglumide."3.68Influence of the CCK-antagonist loxiglumide on bile-induced experimental pancreatitis. ( Creutzfeldt, W; Fussek, M; Leonhardt, U; Seidensticker, F; Stöckmann, F, 1991)
"We evaluated the effects of a new cholecystokinin (CCK) receptor antagonist, loxiglumide, in a model of mild pancreatitis induced by repeated injections of cerulein and in a severe necrotizing form of pancreatitis induced by retrograde ductal injection of sodium taurocholate (NaTc) in rats."3.68Effect of a new cholecystokinin receptor antagonist loxiglumide on acute pancreatitis in two experimental animal models. ( Fujii, M; Itoh, H; Nakamura, T; Okabayashi, Y; Otsuki, M; Tani, S, 1990)
"The effects of the cholecystokinin (CCK)-receptor antagonist proglumide, the protease inhibitor gabexate, and the hormones secretin and cholecystokinin-octapeptide (CCK-8) were studied in a model of acute hemorrhagic pancreatitis induced by feeding mice a choline-deficient, ethionine-supplemented (CDE) diet."3.67Beneficial effects of cholecystokinin-receptor blockade and inhibition of proteolytic enzyme activity in experimental acute hemorrhagic pancreatitis in mice. Evidence for cholecystokinin as a major factor in the development of acute pancreatitis. ( Ferrell, LD; Grendell, JH; Liddle, RA; Niederau, C, 1986)
"Rats with acute experimental pancreatitis were treated with the cholecystokinin (CCK)-receptor antagonist proglumide."3.67Proglumide treatment in bile-induced acute experimental pancreatitis. ( Ihse, I; Larsson, L; Lilja, I; Tarpila, E, 1988)
"The effects of cholecystokinin receptor antagonist CR 1392 was studied in a model of mild acute pancreatitis induced in rats by four subcutaneous injections of the secretagogue caerulein."3.67Effect of a new cholecystokinin receptor antagonist CR 1392 on caerulein-induced acute pancreatitis in rats. ( Baba, S; Fujii, M; Fujisawa, T; Itoh, H; Nakamura, T; Okabayshi, Y; Otsuki, M; Tani, S, 1989)
"The aim of this study was to elucidate whether cholecystokinin (CCK) had a role in the occurrence and/or in the development of experimental acute pancreatitis in rats, and furthermore to find the possibility for the treatment of acute pancreatitis with a CCK antagonist, proglumide."3.67Possible role of cholecystokinin in the development of acute pancreatitis in rats. ( Fujimura, M; Shinya, H, 1989)
"Acute pancreatitis was induced in rats by intravenous infusion of 20 microg/kg/h cerulein for 4 h."1.30CCK administration after CCK receptor blockade accelerates recovery from cerulein-induced acute pancreatitis in rats. ( Kihara, Y; Nakano, S; Otsuki, M, 1998)
"Loxiglumide treatment, although significantly decreasing protein output, had no influence on pancreatic weight, protein and DNA contents, or pancreatic juice flow but increased the amylase and lipase contents compared to those of the saline-treated postpancreatitic rats."1.29Effect of the cholecystokinin receptor antagonist loxiglumide on pancreatic exocrine function in rats after acute pancreatitis. ( Nakano, S; Otsuki, M; Tachibana, I, 1995)
"Treatment with loxiglumide (50 mg/kg body weight), CCK-8 (2."1.29Treatment with cholecystokinin receptor antagonist loxiglumide enhances insulin response to intravenous glucose stimulation in postpancreatitic rats. ( Nakano, S; Otsuki, M; Tachibana, I, 1994)
"The histological signs of acute pancreatitis were greatly alleviated by fasting."1.28Fasting prevents acute pancreatitis induced by cerulein in rats. ( Fujii, M; Fujisawa, T; Itoh, H; Koide, M; Nakamura, T; Okabayashi, Y; Otsuki, M; Tani, S, 1990)
" CR-1409 completely abolished the adverse effects of hydrocortisone on pancreatitis."1.28Involvement of cholecystokinin receptors in the adverse effect of glucocorticoids on diet-induced necrotizing pancreatitis. ( Gomez, G; Green, D; Rajaraman, S; Thompson, JC; Townsend, CM; Uchida, T, 1989)
"Loxiglumide has a simple, non-polypeptidic chemical structure and may be a candidate for clinical investigations in man, e."1.27Loxiglumide protects against experimental pancreatitis. ( Bani, M; Cereda, R; Chisté, R; Makovec, F; Pacini, MA; Revel, L; Setnikar, I, 1987)

Research

Studies (34)

TimeframeStudies, this research(%)All Research%
pre-19908 (23.53)18.7374
1990's20 (58.82)18.2507
2000's4 (11.76)29.6817
2010's2 (5.88)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Smith, JP1
Cooper, TK1
McGovern, CO1
Gilius, EL1
Zhong, Q1
Liao, J1
Molinolo, AA1
Gutkind, JS1
Matters, GL1
Jia, D1
Yamamoto, M2
Otsuki, M10
Shiratori, K1
Takeuchi, T1
Satake, K2
Matsuno, S1
Latorre, M1
Bartolomé-Nebreda, JM1
García-López, MT1
González-Muñiz, R1
Herranz, R1
Del Río, J1
Cenarruzabeitia, E1
Takase, K1
Ueda, T1
Kuroda, Y1
Nakano, S3
Tachibana, I2
Nakae, Y1
Naruse, S1
Kitagawa, M1
Hirao, S1
Yamamoto, R1
Hayakawa, T1
Tani, S6
Itoh, H5
Koide, M2
Okabayashi, Y4
Tomita, H1
Miyasaka, K1
Jimi, A1
Mishima, Y1
Funakoshi, A1
Wang, ZH1
Ohshio, G1
Okada, N1
Imamura, T1
Tanaka, T1
Kohmoto, M1
Yoshida, M1
Tanaka, J1
Arii, S1
Sasaoki, T1
Funaki, N1
Imamura, M1
Song, W1
Yamaguchi, H1
Nakano, I1
Kimura, T1
Nawata, H1
Taniguchi, H2
Yazaki, N1
Yomota, E2
Shikano, T2
Endo, T2
Nagasaki, M2
Czakó, L1
Kume, E1
Rodríguez-Martín, E1
Alvaro-Alonso, I1
Bodega, G1
Arilla, E1
Kihara, Y1
Kimura, K1
Tominaga, K1
Fujii, M4
Saito, T1
Kasai, H1
Ochi, K1
Harada, H1
McCleane, GJ1
Fuji, M1
Nakamura, T4
Fujisawa, T3
Larsen, F1
Schlarman, D1
Andrus, CC1
Kaminski, DL1
Leonhardt, U1
Seidensticker, F1
Fussek, M1
Stöckmann, F1
Creutzfeldt, W1
Grönroos, JM1
Aho, HJ1
Hietaranta, AJ1
Nevalainen, TJ1
Niederau, C2
Liddle, RA1
Ferrell, LD2
Grendell, JH2
Tarpila, E1
Larsson, L1
Lilja, I1
Ihse, I1
Okabayshi, Y1
Baba, S1
Gomez, G1
Townsend, CM1
Green, D1
Rajaraman, S1
Uchida, T1
Thompson, JC1
Shinya, H1
Fujimura, M1
Setnikar, I1
Bani, M1
Cereda, R1
Chisté, R1
Makovec, F1
Pacini, MA1
Revel, L1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase II Study to Establish the Efficacy of Synthetic Human SecretiN in Human Acute Pancreatitis (SNAP) Study[NCT03686618]Phase 240 participants (Anticipated)Interventional2018-10-01Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for proglumide and Acute Edematous Pancreatitis

ArticleYear
[New aspects of pharmaco-therapy for acute pancreatitis].
    Nihon rinsho. Japanese journal of clinical medicine, 2004, Volume: 62, Issue:11

    Topics: Acute Disease; Animals; Blood Proteins; Clinical Trials as Topic; Drug Design; Humans; Imidazoles; L

2004

Trials

2 trials available for proglumide and Acute Edematous Pancreatitis

ArticleYear
Clinical evaluation of oral administration of a cholecystokinin-A receptor antagonist (loxiglumide) to patients with acute, painful attacks of chronic pancreatitis: a multicenter dose-response study in Japan.
    Pancreas, 2002, Volume: 25, Issue:1

    Topics: Acute Disease; Administration, Oral; Adult; Amylases; Chronic Disease; Female; Hormone Antagonists;

2002
Clinical evaluation of cholecystokinin-A- receptor antagonist (loxiglumide) for the treatment of acute pancreatitis. A preliminary clinical trial. Study Group of Loxiglumide in Japan.
    Digestion, 1999, Volume: 60 Suppl 1

    Topics: Abdominal Pain; Acute Disease; Adult; Amylases; Dose-Response Relationship, Drug; Female; Hormone An

1999

Other Studies

31 other studies available for proglumide and Acute Edematous Pancreatitis

ArticleYear
Cholecystokinin receptor antagonist halts progression of pancreatic cancer precursor lesions and fibrosis in mice.
    Pancreas, 2014, Volume: 43, Issue:7

    Topics: Animals; Carcinoma in Situ; Cholecystokinin; Disease Progression; Drug Screening Assays, Antitumor;

2014
Effect of endogenous cholecystokinin on the course of acute pancreatitis in rats.
    World journal of gastroenterology, 2015, Jul-07, Volume: 21, Issue:25

    Topics: Administration, Oral; Animals; Biomarkers; Bombesin; Cell Proliferation; Cholecystokinin; Disease Mo

2015
Pharmacological study of IQM-97,423, a potent and selective CCK1 receptor antagonist with protective effect in experimental acute pancreatitis.
    Pharmacology, 2004, Volume: 72, Issue:2

    Topics: Acute Disease; alpha-Amylases; Animals; Binding, Competitive; Cerebral Cortex; Cholecystokinin; Deva

2004
Effect of the cholecystokinin receptor antagonist loxiglumide on pancreatic exocrine function in rats after acute pancreatitis.
    Pancreas, 1995, Volume: 10, Issue:3

    Topics: Acute Disease; Amylases; Animals; DNA; Lipase; Male; Pancreas; Pancreatitis; Proglumide; Proteins; R

1995
Activation of trypsinogen in experimental models of acute pancreatitis in rats.
    Pancreas, 1995, Volume: 10, Issue:3

    Topics: Acute Disease; alpha-Macroglobulins; Animals; Benzamidines; Ceruletide; Disease Models, Animal; Guan

1995
Involvement of endogenous cholecystokinin in the development of acute pancreatitis induced by closed duodenal loop.
    Pancreas, 1993, Volume: 8, Issue:1

    Topics: Acute Disease; Amylases; Animals; Cholecystokinin; Disease Models, Animal; Duodenum; Lipase; Male; P

1993
Lack of effect of cholecystokinin receptor antagonist (CR1505) on recovery of experimental pancreatitis after pancreatic duct occlusion in rats.
    Pancreas, 1994, Volume: 9, Issue:5

    Topics: Animals; Body Weight; Cholecystokinin; Duodenum; Eating; Intestinal Mucosa; Ligation; Male; Organ Si

1994
Treatment with cholecystokinin receptor antagonist loxiglumide enhances insulin response to intravenous glucose stimulation in postpancreatitic rats.
    Regulatory peptides, 1994, Jul-14, Volume: 52, Issue:2

    Topics: Acute Disease; Animals; Ceruletide; Glucose; Injections, Intravenous; Injections, Subcutaneous; Insu

1994
Effects of cholecystokinin and carbachol on membrane fluidity in pancreatic acini.
    Digestive diseases and sciences, 1996, Volume: 41, Issue:7

    Topics: Animals; Bombesin; Carbachol; Cholecystokinin; Dose-Response Relationship, Drug; Hormone Antagonists

1996
Role of endogenous cholecystokinin in the regeneration of pancreatic tissue after acute hemorrhagic pancreatitis in rats.
    Fukuoka igaku zasshi = Hukuoka acta medica, 1996, Volume: 87, Issue:1

    Topics: Acute Disease; Animals; Cholecystokinin; Hemorrhage; Male; Pancreas; Pancreatitis; Proglumide; Rats;

1996
Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vivo.
    European journal of pharmacology, 1996, Sep-26, Volume: 312, Issue:2

    Topics: Animals; Benzodiazepinones; Ceruletide; Devazepide; Dogs; Female; Gastric Emptying; Indoles; Male; P

1996
Pancreatic fluid hypersecretion in rats after acute pancreatitis.
    Digestive diseases and sciences, 1997, Volume: 42, Issue:2

    Topics: Acute Disease; Animals; Antibodies; Atropine; Bicarbonates; Cell Division; Ceruletide; Chlorides; Ch

1997
Effect of T-0632, a cholecystokininA receptor antagonist, on experimental acute pancreatitis.
    Japanese journal of pharmacology, 1997, Volume: 73, Issue:2

    Topics: Acute Disease; Amylases; Animals; Ceruletide; Disease Models, Animal; Dogs; Esters; Female; Gabexate

1997
The somatostatin receptor-adenylate cyclase system in rat pancreatic acinar membranes after temporary pancreaticobiliary duct ligation.
    Life sciences, 1997, Volume: 61, Issue:23

    Topics: Adenylyl Cyclases; Animals; Cholestasis; Ligation; Male; Pancreas; Pancreatitis; Proglumide; Rats; R

1997
CCK administration after CCK receptor blockade accelerates recovery from cerulein-induced acute pancreatitis in rats.
    Pancreas, 1998, Volume: 16, Issue:2

    Topics: Acute Disease; Amylases; Animals; Ceruletide; Cholecystokinin; DNA; Hormone Antagonists; Lipase; Mal

1998
Effects of loxiglumide on experimental acute pancreatitis in comparison with gabexate mesilate.
    Arzneimittel-Forschung, 1998, Volume: 48, Issue:1

    Topics: Acute Disease; Amylases; Animals; Ceruletide; Duodenum; Female; Gabexate; Hormone Antagonists; Injec

1998
The cholecystokinin antagonist proglumide has an analgesic effect in chronic pancreatitis.
    Pancreas, 2000, Volume: 21, Issue:3

    Topics: Adult; Analgesia; Cholecystokinin; Chronic Disease; Humans; Male; Pancreas; Pancreatitis; Proglumide

2000
Beneficial effects of the synthetic trypsin inhibitor camostate in cerulein-induced acute pancreatitis in rats.
    Digestive diseases and sciences, 1990, Volume: 35, Issue:2

    Topics: Acute Disease; Amylases; Animals; Ceruletide; Esters; Gabexate; Guanidines; Male; Organ Size; Pancre

1990
The effect of the CCK receptor antagonist CR 1409 on bile reflux pancreatitis in the opossum.
    Pancreas, 1991, Volume: 6, Issue:3

    Topics: Amylases; Animals; Bile Reflux; Cholecystokinin; Common Bile Duct; Female; Glucagon; Insulin; Ligati

1991
Influence of the CCK-antagonist loxiglumide on bile-induced experimental pancreatitis.
    International journal of pancreatology : official journal of the International Association of Pancreatology, 1991, Volume: 10, Issue:1

    Topics: Animals; Male; Pancreatitis; Proglumide; Rats; Rats, Inbred Strains; Receptors, Cholecystokinin; Tau

1991
Early acinar cell changes in caerulein-induced interstitial acute pancreatitis in the rat.
    Experimental pathology, 1991, Volume: 41, Issue:1

    Topics: Acute Disease; Animals; Ceruletide; Cycloleucine; Cytoplasm; Cytoplasmic Granules; Enzyme Precursors

1991
Effect of a new cholecystokinin receptor antagonist loxiglumide on acute pancreatitis in two experimental animal models.
    Pancreas, 1990, Volume: 5, Issue:3

    Topics: Acute Disease; Animals; Ceruletide; Cholecystokinin; Disease Models, Animal; Glutamine; Male; Pancre

1990
Fasting prevents acute pancreatitis induced by cerulein in rats.
    Digestive diseases and sciences, 1990, Volume: 35, Issue:7

    Topics: Acute Disease; Animals; Ceruletide; Cholecystokinin; Fasting; Male; Pancreas; Pancreatitis; Proglumi

1990
Beneficial effects of cholecystokinin-receptor blockade and inhibition of proteolytic enzyme activity in experimental acute hemorrhagic pancreatitis in mice. Evidence for cholecystokinin as a major factor in the development of acute pancreatitis.
    The Journal of clinical investigation, 1986, Volume: 78, Issue:4

    Topics: Acute Disease; Amylases; Animals; Cholecystokinin; Choline Deficiency; Disease Models, Animal; Ethio

1986
Proglumide treatment in bile-induced acute experimental pancreatitis.
    International journal of pancreatology : official journal of the International Association of Pancreatology, 1988, Volume: 3, Issue:2-3

    Topics: Acute Disease; Amylases; Animals; Bile; Glutamine; Male; Pancreatitis; Proglumide; Rats; Rats, Inbre

1988
Effect of a new cholecystokinin receptor antagonist CR 1392 on caerulein-induced acute pancreatitis in rats.
    Pancreas, 1989, Volume: 4, Issue:2

    Topics: Acute Disease; Amylases; Animals; Ceruletide; Glutamine; Humans; Male; Organ Size; Pancreas; Pancrea

1989
Involvement of cholecystokinin receptors in the adverse effect of glucocorticoids on diet-induced necrotizing pancreatitis.
    Surgery, 1989, Volume: 106, Issue:2

    Topics: Amylases; Animals; Choline Deficiency; Diet; Dose-Response Relationship, Drug; Ethionine; Female; Gl

1989
Possible role of cholecystokinin in the development of acute pancreatitis in rats.
    Nihon geka hokan. Archiv fur japanische Chirurgie, 1989, Jan-01, Volume: 58, Issue:1

    Topics: Acute Disease; Animals; Cholecystokinin; Male; Pancreatitis; Proglumide; Rats; Rats, Inbred Strains

1989
Caerulein-induced acute necrotizing pancreatitis in mice: protective effects of proglumide, benzotript, and secretin.
    Gastroenterology, 1985, Volume: 88, Issue:5 Pt 1

    Topics: Acute Disease; Animals; Benzamides; Ceruletide; Dose-Response Relationship, Drug; Glutamine; Male; M

1985
Experimental acute pancreatitis induced by excessive doses of caerulein in rats; protective and therapeutic effects of trypsin inhibitor urinastatin and CCK receptor antagonist CR1392.
    The Kobe journal of medical sciences, 1988, Volume: 34, Issue:2

    Topics: Acute Disease; Animals; Ceruletide; Disease Models, Animal; Dose-Response Relationship, Drug; Glutam

1988
Loxiglumide protects against experimental pancreatitis.
    Arzneimittel-Forschung, 1987, Volume: 37, Issue:10

    Topics: Animals; Ceruletide; Diet; Female; Glutamine; Male; Mice; Pancreatitis; Proglumide; Rats; Rats, Inbr

1987